Aberdeen Group plc Sells 61,228 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Aberdeen Group plc lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 28.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 157,396 shares of the biopharmaceutical company’s stock after selling 61,228 shares during the quarter. Aberdeen Group plc owned 0.12% of Alnylam Pharmaceuticals worth $71,720,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the third quarter valued at $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $27,000. Atlantic Union Bankshares Corp bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $30,000. ORG Partners LLC boosted its position in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 33 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $37,000. Institutional investors own 92.97% of the company’s stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Amvuttra is powering large revenue gains and Alnylam reported full-year product revenues near $3B with strong year‑over‑year growth; the company also reported profitability for the first time — a clear fundamental positive for long‑term earnings potential. Business Wire: Alnylam Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Catalyst from analyst support — some firms (e.g., TD Cowen) are maintaining Buy ratings and framing Amvuttra as the catalyst for a longer‑term profitability inflection. TipRanks: Amvuttra-Driven Profitability Inflection Supports Buy Rating
• Neutral Sentiment: FY‑2026 revenue guidance was updated to roughly $5.3–$5.8B (slightly wide band vs. consensus), leaving mixed readthroughs for near‑term estimates and valuation models. Business Wire: FY‑2026 Guidance
• Neutral Sentiment: Analysts have trimmed price targets (e.g., Chardan, Needham) but many kept Buy ratings — this tempers upside expectations while still signaling continued institutional conviction. Benzinga: Analyst Price Target Changes
• Negative Sentiment: Market reaction to the Q4 release was mixed: some outlets flagged EPS and revenue misses vs. specific consensus numbers while others reported an EPS beat — the inconsistent takeaways have created volatility and investor uncertainty. Zacks: Q4 Earnings Beat, Sales Miss MarketBeat: Q4 Snapshot
• Negative Sentiment: Management signaled higher long‑term R&D/spend to fund pipeline ambitions and flagged execution/scaling risks for global Amvuttra rollout — comments that prompted some investors to downgrade longer‑term profit expectations. Seeking Alpha: Investors Revise Future Profit Expectations TipRanks: Execution Risks Loom
• Neutral Sentiment: Reported short‑interest figures in the feeds are effectively zero/placeholder and not informative for current positioning — ignore as a market signal until clearer data is posted.

Analyst Ratings Changes

ALNY has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Wells Fargo & Company decreased their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Finally, Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday. Twenty-two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $477.38.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $314.40 on Monday. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The stock has a market cap of $41.70 billion, a PE ratio of 183.86 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The business’s 50-day moving average price is $374.98 and its two-hundred day moving average price is $425.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the previous year, the business posted ($0.65) earnings per share. The business’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,510 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the transaction, the executive vice president owned 29,728 shares in the company, valued at approximately $10,787,399.36. This represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the transaction, the executive vice president owned 57,465 shares in the company, valued at $20,852,324.55. This represents a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 19,177 shares of company stock worth $6,975,746 over the last 90 days. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.